September 11th 2025
Head-to-head phase 1 data indicate larger fecal IgA responses after a single tablet vs first-generation constructs, with plans to advance to mid-stage testing.
September 9th 2025
Cocrystal Pharma to launch phase 1b study by year-end 2025, targeting prevention and treatment of viral gastroenteritis caused by norovirus.
March 6th 2025
Phase 1b trial data demonstrated immune response, with 85% reduction in viral shedding and robust mucosal immunity in elderly adults.
February 3rd 2025
Prashant Kumar’s study on indoor air quality aboard cruise ships highlights the critical role of ventilation and masking in reducing infection risks.
January 23rd 2025
Sasirekha Ramani, PhD, discusses the potential of 2′FL as a treatment for norovirus and what more research could reveal.
College Officials Still Don't Know What Has Sickened 174 Students
In just about 24 hours, the number of students at Ursinus College in Collegeville, Pennsylvania experiencing an unidentified stomach illness has increased from 40 to 174.
Read More
Researchers Grow Human Norovirus Culture
Hoping their discovery will lead to novel treatments, University of Florida researchers have successfully manufactured the human norovirus in a cell culture dish.